awacke1/LOINC-Clinical-Terminology · Datasets at Hugging Face

LOINC_NUM stringlengths 3 8	COMPONENT stringlengths 2 246	PROPERTY stringlengths 1 29	TIME_ASPCT stringlengths 1 15	SYSTEM stringlengths 1 106	SCALE_TYP stringclasses 10 values	METHOD_TYP stringlengths 1 57 ⌀	CLASS stringlengths 2 24	CLASSTYPE int64 1 4	LONG_COMMON_NAME stringlengths 3 254	SHORTNAME stringlengths 2 51 ⌀	EXTERNAL_COPYRIGHT_NOTICE stringlengths 39 2.6k ⌀	STATUS stringclasses 4 values	VersionFirstReleased stringlengths 1 7	VersionLastChanged stringlengths 1 5
96990-7	Vaccine administration location	Type	Pt	^Event	Nom	null	VACCIN	2	Vaccine administration location	Vaccine administration loc	null	ACTIVE	2.70	2.7
96991-5	Vaccine administration county	Loc	Pt	^Event	Nom	null	VACCIN	2	Vaccine administration county [Location]	Vaccine administration county	null	ACTIVE	2.70	2.7
96992-3	Vaccine administration state	Loc	Pt	^Event	Nom	null	VACCIN	2	State where vaccine was administered	Vaccine administration state	null	ACTIVE	2.70	2.7
96993-1	Federal agency code	ID	Pt	Agency	Nom	null	ADMIN	2	Federal agency code	Federal agency code	null	ACTIVE	2.70	2.7
96994-9	Vaccine doses distributed	Num	Pt	^Event	Qn	null	VACCIN	2	Vaccine doses distributed [#]	Vaccine doses distributed	null	ACTIVE	2.70	2.7
96995-6	Vaccine doses distributed/100,000 population	NRto	Pt	^Event	Qn	null	VACCIN	2	Total vaccine doses distributed per 100,000 population	Vac doses dist per 100,000	null	ACTIVE	2.70	2.7
96996-4	People who have received first dose of vaccine	Num	Pt	^Population	Qn	null	VACCIN	2	People who have received first dose of vaccine [#] Population	People rcvd first dose of vaccine Pop	null	ACTIVE	2.70	2.7
96997-2	People who have received first dose of vaccine/100,000 population	NFr	Pt	^Population	Qn	null	VACCIN	2	Count of people who initiated vaccination per 100,000 population	Rcvd first dose of vaccine/100,00 pop	null	ACTIVE	2.70	2.7
96998-0	People who are fully vaccinated	Num	Pt	^Population	Qn	null	VACCIN	2	Count of people who are fully vaccinated in Population	People who fully vaccinated Pop	null	ACTIVE	2.70	2.7
96999-8	People who are fully vaccinated/100,000 population	NFr	Pt	^Population	Qn	null	VACCIN	2	Count of people who are fully vaccinated per 100,000 population	People who fully vaccinated/100,000 pop	null	ACTIVE	2.70	2.7
97000-4	Vaccine doses distributed for use in long term care facilities	Num	Pt	^Event	Qn	null	VACCIN	2	Vaccine doses distributed for use in long term care facilities [#]	Vaccine doses distributed to LTCFs	null	ACTIVE	2.70	2.7
97001-2	Vaccine administration tier	Type	Pt	^Event	Nom	null	VACCIN	2	Vaccine administration tier	Vaccine administration tier	null	ACTIVE	2.70	2.7
97002-0	People in long-term care facilities who have received first dose of vaccine	Num	Pt	^Population	Qn	null	VACCIN	2	Number of people in long-term care facilities who have received first dose of vaccine	# People in LTCFs rcvd 1st dose vaccine	null	ACTIVE	2.70	2.7
97003-8	People in long-term care facilities who are fully vaccinated	Num	Pt	^Population	Qn	null	VACCIN	2	Number of people in long-term care facilities who are fully vaccinated	# People in LTCFs fully vaccinated	null	ACTIVE	2.70	2.7
97004-6	Insulin type	Prid	Pt	Ser/Plas	Nom	LC/MS/MS	CHEM	1	Insulin type [Identifier] in Serum or Plasma by LC/MS/MS	Insulin Type SerPl LC/MS/MS	null	ACTIVE	2.70	2.7
97005-3	Maximum clot strength amplitude.kaolin+tissue factor induced	Len	Pt	Bld	Qn	Thromboelastography.resonance	COAG	1	Maximum amplitude kaolin+tissue factor induced [Length] in Blood by Resonance TEG	MA kaolin+TF Bld Res TEG	null	ACTIVE	2.70	2.7
9700-6	Procaine	MCnc	Pt	Ser/Plas	Qn	null	DRUG/TOX	1	Procaine [Mass/volume] in Serum or Plasma	Procaine SerPl-mCnc	null	ACTIVE	1.0i	2.73
97006-1	Maximum clot strength amplitude.kaolin+tissue factor induced	Len	Pt	Bld	Qn	null	COAG	1	Maximum amplitude kaolin+tissue factor induced [Length] in Blood	MA kaolin+TF Bld	null	ACTIVE	2.70	2.7
97007-9	Clot initiation.kaolin induced^post heparin neutralization	Time	Pt	Bld	Qn	Thromboelastography.resonance	COAG	1	Clot initiation.kaolin induced [Time] in Blood by Resonance TEG --post heparin neutralization	Clot init kao ind p hep neut Bld Res TEG	null	ACTIVE	2.70	2.7
97008-7	Clot initiation.kaolin+tissue factor induced	Time	Pt	Bld	Qn	null	COAG	1	Clot initiation.kaolin+tissue factor induced [Time] in Blood	Clot init kaolin+TF ind Bld	null	ACTIVE	2.70	2.7
97009-5	Activated clotting time.kaolin+tissue factor induced	Time	Pt	Bld	Qn	Calculated	COAG	1	Activated clotting time.kaolin+tissue factor induced of Blood by calculation	ACT Kaolin+TF Ind Bld Calc	null	ACTIVE	2.70	2.7
97010-3	Clot formation.kaolin+tissue factor induced	Time	Pt	Bld	Qn	null	COAG	1	Clot formation kaolin+tissue factor induced [Time] in Blood	CFT kaolin+TF ind Bld	null	ACTIVE	2.70	2.7
97011-1	Clot angle.kaolin+tissue factor induced	Angle	Pt	Bld	Qn	null	COAG	1	Clot angle kaolin+tissue factor induced in Blood	Clot angle kaolin+TF ind Bld	null	ACTIVE	2.70	2.7
97012-9	Reduction in clot strength.kaolin+tissue factor induced^30M post maximum clot amplitude	LenFr	Pt	Bld	Qn	null	COAG	1	Reduction in kaolin+tissue factor induced clot strength [Length fraction] in Blood --30 minutes post maximum clot amplitude	Lysis kao+TF ind clot 30M p MA LenFr Bld	null	ACTIVE	2.70	2.7
97013-7	Reduction in clot strength.kaolin induced^30M post maximum clot amplitude	LenFr	Pt	Bld	Qn	Thromboelastography.resonance	COAG	1	Reduction in kaolin induced clot strength [Length fraction] in Blood by Resonance TEG --30 minutes post maximum clot amplitude	Lys kao ind clt 30M p MA LenFr Bl ResTEG	null	ACTIVE	2.70	2.7
9701-4	sulfiSOXAZOLE	MCnc	Pt	Ser/Plas	Qn	null	DRUG/TOX	1	sulfiSOXAZOLE [Mass/volume] in Serum or Plasma	Sulfisoxaz SerPl-mCnc	null	ACTIVE	1.0i	2.7
97014-5	Maximum clot strength amplitude.tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited	Len	Pt	Bld	Qn	Thromboelastography.resonance	COAG	1	Maximum amplitude tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited [Length] in Blood by Resonance TEG	MA TF ind+IIb-IIIa inh Bld Res TEG	null	ACTIVE	2.70	2.7
97015-2	Maximum clot strength amplitude.tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited	Len	Pt	Bld	Qn	null	COAG	1	Maximum amplitude tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited [Length] in Blood	MA TF ind+IIb-IIIa inh Bld	null	ACTIVE	2.70	2.7
97016-0	Fibrinogen	MCnc	Pt	Bld	Qn	Calculated	COAG	1	Fibrinogen [Mass/volume] in Blood by calculation	Fibrinogen Bld Calc-mCnc	null	ACTIVE	2.70	2.7
97017-8	Maximum clot strength amplitude.kaolin induced^after addition of heparinase	Len	Pt	Bld	Qn	null	COAG	1	Maximum amplitude kaolin induced [Length] in Blood --after addition of heparinase	MA kaolin P Hpase Bld	null	ACTIVE	2.70	2.7
97018-6	Maximum clot strength amplitude.activator F induced	Len	Pt	Bld	Qn	null	COAG	1	Maximum amplitude activator F induced [Length] in Blood	MA ActF Bld	null	ACTIVE	2.70	2.7
97019-4	Maximum clot strength amplitude.adenosine diphosphate induced	Len	Pt	Bld	Qn	null	COAG	1	Maximum amplitude ADP induced [Length] in Blood	MA ADP Bld	null	ACTIVE	2.70	2.7
97020-2	Maximum clot strength amplitude.arachidonate induced	Len	Pt	Bld	Qn	null	COAG	1	Maximum amplitude arachidonate induced [Length] in Blood	MA AA Bld	null	ACTIVE	2.70	2.7
97021-0	Reduction in clot strength.kaolin induced^30M post maximum clot amplitude	LenFr	Pt	Bld	Qn	null	COAG	1	Reduction in kaolin induced clot strength [Length fraction] in Blood --30 minutes post maximum clot amplitude	Lys of kao ind clot 30M p MA LenFr Bld	null	ACTIVE	2.70	2.7
9702-2	Terbutaline	MCnc	Pt	Ser/Plas	Qn	null	DRUG/TOX	1	Terbutaline [Mass/volume] in Serum or Plasma	Terbutaline SerPl-mCnc	null	ACTIVE	1.0i	2.7
97022-8	Clot strength.arachidonate inhibited	LenFr	Pt	Bld	Qn	Calculated	COAG	1	Clot strength arachidonate inhibited [Length fraction] in Blood by calculation	Clot strength AA inhib LenFr Bld Calc	null	ACTIVE	2.70	2.7
97023-6	Accountable health communities health-related social needs supplemental questions	-	Pt	^Patient	-	null	PANEL.SURVEY.GNHLTH	4	Accountable health communities (AHC) health-related social needs (HRSN) supplemental questions	null	null	ACTIVE	2.70	2.7
97024-4	aPTT mixing study panel	-	Pt	PPP	-	null	PANEL.COAG	1	aPTT mixing study panel - Platelet poor plasma	aPTT Mix Pnl PPP	null	ACTIVE	2.70	2.7
97025-1	BRAF gene.p.Val600 mutations	Prid	Pt	Tiss	Nom	Molgen	MOLPATH.MUT	1	BRAF gene V600 mutations [Identifier] in Tissue by Molecular genetics method Nominal	BRAF p.V600 mutations Tiss	null	ACTIVE	2.70	2.7
97026-9	Phosphatidylserine-prothrombin complex Ab.IgG & IgM panel	-	Pt	Ser/Plas	-	null	PANEL.COAG	1	Phosphatidylserine-prothrombin complex IgG and IgM panel - Serum or Plasma	PS-prothrom cmplx IgG IgM Pnl SerPl	null	ACTIVE	2.70	2.7
97027-7	Speaks a language other than English at home	Find	Pt	^Patient	Ord	null	SURVEY.GNHLTH	4	Speaks a language other than English at home	null	null	ACTIVE	2.70	2.7
97029-3	Spine Tango surgery follow-up 2017	-	Pt	^Patient	-	Spine Tango	PANEL.SURG	2	Spine Tango surgery follow-up 2017 Spine Tango	Spine Tango surgery f/u 2017 Spine Tango	Copyright © 2020 EUROSPINE. All rights reserved.	ACTIVE	2.70	2.7
9703-0	Trihexyphenidyl	MCnc	Pt	Ser/Plas	Qn	null	DRUG/TOX	1	Trihexyphenidyl [Mass/volume] in Serum or Plasma	Trihexyphenidyl SerPl-mCnc	null	ACTIVE	1.0i	2.7
97030-1	Level of spine intervention	Find	Pt	^Patient	Nom	null	SURG	2	Level of spine intervention	Level of spine intervention	null	ACTIVE	2.70	2.7
97031-9	Follow-up panel	-	Pt	^Patient	-	Spine Tango	PANEL.SURG	2	Follow-up panel Spine Tango	Spine Tango	Copyright © 2020 EUROSPINE. All rights reserved.	ACTIVE	2.70	2.7
97032-7	Postoperative follow-up interval	Find	Pt	^Patient	Nom	null	H&P.HX	2	Postoperative follow-up interval	Postop follow-up interval	null	ACTIVE	2.70	2.7
97033-5	Postoperative work status	Find	Pt	^Patient	Nom	null	SURVEY.GNHLTH	4	Postoperative work status	null	null	ACTIVE	2.70	2.7
97034-3	Postoperative therapeutic goals or measures that were achieved	Find	Pt	^Patient	Nom	null	SURG	2	Postoperative therapeutic goals or measures that were achieved	Postop ther goals achieved	null	ACTIVE	2.70	2.7
97035-0	Postoperative therapeutic goals or measures that were partially achieved	Find	Pt	^Patient	Nom	null	SURG	2	Postoperative therapeutic goals or measures that were partially achieved	Postop ther goals partially achieved	null	ACTIVE	2.70	2.7
97036-8	Postoperative therapeutic goals or measures that were not achieved	Find	Pt	^Patient	Nom	null	SURG	2	Postoperative therapeutic goals or measures that were not achieved	Postop ther goals not achieved	null	ACTIVE	2.70	2.7
97037-6	Medication for spinal surgery or pathology	Find	Pt	^Patient	Nom	null	SURG	2	Medication for spinal surgery or pathology	Meds spinal surgery/pathology	null	ACTIVE	2.70	2.7
97038-4	Postoperative rehabilitation	Find	Pt	^Patient	Nom	null	SURG	2	Postoperative rehabilitation	Postop rehab	null	ACTIVE	2.70	2.7
97039-2	Overall outcome of spine surgery	Find	Pt	^Patient	Nom	null	SURG	2	Overall outcome of spine surgery	Overall outcome of spine surgery	null	ACTIVE	2.70	2.7
970-4	Weak D Ag	PrThr	Pt	RBC^BPU	Ord	null	BLDBK	1	Weak D Ag [Presence] on Red Blood Cells from Blood product unit	Weak D Ag RBC BPU Ql	null	ACTIVE	1.0	2.7
97040-0	Postoperative follow-up care decision	Find	Pt	^Patient	Nom	null	SURG	2	Postoperative follow-up care decision	Postop follow-up care decision	null	ACTIVE	2.70	2.7
97041-8	Comments regarding postoperative follow-up	Find	Pt	^Patient	Nom	null	SURG	2	Comments regarding postoperative follow-up	Comments re: postop follow-up	null	ACTIVE	2.70	2.7
97042-6	Complications panel	-	Pt	^Patient	-	Spine Tango	PANEL.SURG	2	Complications panel Spine Tango	Complications pnl Spine Tango	Copyright © 2020 EUROSPINE. All rights reserved.	ACTIVE	2.70	2.7
97043-4	Postoperative complication occurred	Find	Pt	^Patient	Ord	null	SURG	2	Postoperative complication occurred	Postop comp occurred	null	ACTIVE	2.70	2.7
97044-2	Postoperative complication timing	Find	Pt	^Patient	Nom	null	SURG	2	Postoperative complication timing	Postop complication timing	null	ACTIVE	2.70	2.7
97045-9	Postoperative complication type	Find	Pt	^Patient	Nom	null	SURG	2	Postoperative complication type	Postop complication type	null	ACTIVE	2.70	2.7
97046-7	Postoperative complication treatment needed	Find	Pt	^Patient	Nom	null	SURG	2	Postoperative complication treatment needed	Postop complication treatment	null	ACTIVE	2.70	2.7
97047-5	Postoperative complication effect on recovery	Find	Pt	^Patient	Nom	null	SURG	2	Postoperative complication effect on recovery	Postop comp effect on recvry	null	ACTIVE	2.70	2.7
9704-8	Spermatozoa	Morph	Pt	Semen	Nom	null	FERT	1	Spermatozoa [Morphology] in Semen	Sperm Smn	null	ACTIVE	1.0i	2.73
97048-3	Comments regarding postoperative complications	Find	Pt	^Patient	Nom	null	SURG	2	Comments regarding postoperative complications	Comments re: postop complications	null	ACTIVE	2.70	2.7
97049-1	p53 Ab	MCnc	Pt	Ser/Plas	Qn	IA	SERO	1	p53 Ab [Mass/volume] in Serum or Plasma by Immunoassay	p53 Ab SerPl IA-mCnc	null	ACTIVE	2.70	2.7
97050-9	Acinetobacter calcoaceticus-baumannii complex DNA	PrThr	Pt	Bld.pos growth	Ord	Non-probe.amp.tar	MICRO	1	Acinetobacter calcoaceticus-baumannii complex DNA [Presence] by NAA with non-probe detection in Positive blood culture	ACB complex DNA Bld Pos Ql NAA+non-probe	null	ACTIVE	2.70	2.7
97051-7	Interferon.beta	MCnc	Pt	Ser/Plas	Qn	null	CHEM	1	Interferon beta [Mass/volume] in Serum or Plasma	IFN-B SerPl-mCnc	null	ACTIVE	2.70	2.7
97052-5	Chemokine (C-C motif) ligand 2	MCnc	Pt	Ser/Plas	Qn	null	CHEM	1	Chemokine (C-C motif) ligand 2 [Mass/volume] in Serum or Plasma	CCL2 SerPl-mCnc	null	ACTIVE	2.70	2.7
97053-3	Macrophage inflammatory protein 1.alpha	MCnc	Pt	Ser/Plas	Qn	null	CHEM	1	Macrophage inflammatory protein 1 alpha [Mass/volume] in Serum or Plasma	MIP-1 alpha SerPl-mCnc	null	ACTIVE	2.70	2.71
97054-1	Granulocyte macrophage colony stimulating factor	MCnc	Pt	Ser/Plas	Qn	null	CHEM	1	Granulocyte macrophage colony stimulating factor [Mass/volume] in Serum or Plasma	GM-CSF SerPl-mCnc	null	ACTIVE	2.70	2.71
9705-5	Coccidioides immitis Ab.IgA	ACnc	Pt	Ser	Qn	null	MICRO	1	Coccidioides immitis IgA Ab [Units/volume] in Serum	C immitis IgA Ser-aCnc	null	ACTIVE	1.0i	2.73
97055-8	Finnish diabetes risk score panel	-	Pt	^Patient	-	FINDRISC	PANEL.CLIN.RISK	2	Finnish diabetes risk score panel FINDRISC	FINDRISC pnl FINDRISC	null	ACTIVE	2.70	2.7
97057-4	BMI score for risk calculation	Score	Pt	^Patient	Ord	null	H&P.HX	2	BMI score for risk calculation	BMI score for risk calc	null	ACTIVE	2.70	2.7
97058-2	Waist circumference score for risk calculation	Score	Pt	^Patient	Ord	null	H&P.PX	2	Waist circumference score for risk calculation	Waist circ score for risk calc	null	ACTIVE	2.70	2.7
97059-0	Physical activity at least 30M per D	Find	Pt	^Patient	Ord	null	H&P.HX	2	Physical activity at least 30 minutes per day	Physical activity min 30 M/day	null	ACTIVE	2.70	2.7
97060-8	Vegetable &or fruit frequency	NRat	Pt	^Patient	Ord	null	H&P.HX	2	Vegetable AndOr fruit frequency	Vegetable AndOr fruit frequency	null	ACTIVE	2.70	2.7
97062-4	High blood glucose	Hx	Pt	^Patient	Ord	null	H&P.HX	2	History of High blood glucose	Hx of High blood glucose	null	ACTIVE	2.70	2.7
9706-3	Coxiella burnetii phase 1 Ab.IgA	Titr	Pt	Ser	Qn	null	MICRO	1	Coxiella burnetii phase 1 IgA Ab [Titer] in Serum	C burnet Ph1 IgA Titr Ser	null	ACTIVE	1.0i	2.73
97063-2	Diabetes	Hx	Pt	^Family member	Ord	null	H&P.HX	2	Family history of Diabetes	Family hx of Diabetes	null	ACTIVE	2.70	2.7
97064-0	Total risk score	Score	Pt	^Patient	Qn	FINDRISC	CLIN.RISK	2	Total risk score FINDRISC	Total risk score FINDRISC	null	ACTIVE	2.70	2.7
97065-7	Medical history for preventive vaccination against COVID-19 (Coronavirus Disease 2019) - with mRNA vaccine	-	Pt	^Patient	-	null	PANEL.VACCIN	2	Medical history for preventive vaccination against COVID-19 (Coronavirus Disease 2019) - with mRNA vaccine	Hx for COVID -19 vaccine	null	ACTIVE	2.70	2.7
97066-5	Acute illness with fever	Find	Pt	^Patient	Ord	null	H&P.HX	2	Acute illness with fever	Acute ill w/fever	null	ACTIVE	2.70	2.7
97067-3	Allergic reaction to first COVID-19 vaccine dose	Find	Pt	^Patient	Ord	null	VACCIN	2	Allergic reaction to first COVID-19 vaccine dose	Aller react 1st COVID-19 dose	null	ACTIVE	2.70	2.7
97068-1	Chronic diseases &or immunodeficiency	Hx	Pt	^Patient	Ord	null	H&P.HX	2	History of Chronic diseases AndOr immunodeficiency	Hx chronic diseases/immunodeficiency	null	ACTIVE	2.70	2.7
97069-9	Coagulation disorder &or blood-thinning medication use	Hx	Pt	^Patient	Ord	null	H&P.HX	2	History of Coagulation disorder AndOr blood-thinning medication use	Hx coag disorder &/or bld-thin med	null	ACTIVE	2.70	2.7
97070-7	Adverse event following prior vaccination	Find	Pt	^Patient	Ord	null	VACCIN	2	Adverse event following prior vaccination	AE p vaccine	null	ACTIVE	2.70	2.7
9707-1	Coxiella burnetii phase 2 Ab.IgA	Titr	Pt	Ser	Qn	null	MICRO	1	Coxiella burnetii phase 2 IgA Ab [Titer] in Serum	C burnet Ph2 IgA Titr Ser	null	ACTIVE	1.0i	2.73
97071-5	Pregnant or nursing	Find	Pt	^Patient	Ord	null	H&P.HX	2	Pregnant or nursing	Pregnant/Nursing	null	ACTIVE	2.70	2.7
97072-3	Vaccinated in last 14 D	Find	14D	^Patient	Ord	null	VACCIN	2	Vaccinated in last 14 days	Vacc last 14 D	null	ACTIVE	2.70	2.7
97073-1	Received COVID-19 vaccine	Find	Pt	^Patient	Ord	null	VACCIN	2	Received COVID-19 vaccine	Rcvd COVID-19 vaccine	null	ACTIVE	2.70	2.7
97074-9	Mean score	Score	Pt	^Patient	Qn	CRBS	SURVEY.COVID	4	Mean score [CRBS]	null	Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission.	ACTIVE	2.70	2.71
97075-6	Total score	Score	Pt	^Patient	Qn	CAS	SURVEY.COVID	4	Total score [CAS]	null	null	ACTIVE	2.70	2.71
97076-4	Common news sources	Type	Pt	^Patient	Nom	null	SURVEY.COVID	4	Common news sources	null	null	ACTIVE	2.70	2.71
97077-2	Time spent per day getting information about COVID-19 &or its impact	Find	Pt	^Patient	Ord	null	SURVEY.COVID	4	Time spent per day getting information about COVID-19 and/or its impact	null	null	ACTIVE	2.70	2.71
97078-0	Effect of friends, family or neighbors as source of information on mental health	Find	Pt	^Patient	Ord	null	SURVEY.COVID	4	Effect of friends, family or neighbors as source of information on mental health	null	null	ACTIVE	2.70	2.71
97079-8	Effect of local government officials as source of information on mental health	Find	Pt	^Patient	Ord	null	SURVEY.COVID	4	Effect of local government officials as source of information on mental health	null	null	ACTIVE	2.70	2.71
97080-6	Effect of national government officials as source of information on mental health	Find	Pt	^Patient	Ord	null	SURVEY.COVID	4	Effect of national government officials as source of information on mental health	null	null	ACTIVE	2.70	2.71
97081-4	Effect of national and international health officials as source of information on mental health	Find	Pt	^Patient	Ord	null	SURVEY.COVID	4	Effect of national and international health officials as source of information on mental health	null	null	ACTIVE	2.70	2.71
97082-2	Effect of print or online news as source of information on mental health	Find	Pt	^Patient	Ord	null	SURVEY.COVID	4	Effect of print or online news as source of information on mental health	null	null	ACTIVE	2.70	2.71
97083-0	Effect of radio or podcast as source of information on mental health	Find	Pt	^Patient	Ord	null	SURVEY.COVID	4	Effect of radio or podcast as source of information on mental health	null	null	ACTIVE	2.70	2.71

96990-7

Vaccine administration location

Type

Pt

^Event

Nom

null

VACCIN

2

Vaccine administration location

Vaccine administration loc

null

ACTIVE

2.70

2.7

96991-5

Vaccine administration county

Loc

Pt

^Event

Nom

null

VACCIN

2

Vaccine administration county [Location]

Vaccine administration county

null

ACTIVE

2.70

2.7

96992-3

Vaccine administration state

Loc

Pt

^Event

Nom

null

VACCIN

2

State where vaccine was administered

Vaccine administration state

null

ACTIVE

2.70

2.7

96993-1

Federal agency code

ID

Pt

Agency

Nom

null

ADMIN

2

Federal agency code

null

ACTIVE

2.70

2.7

96994-9

Vaccine doses distributed

Num

Pt

^Event

Qn

null

VACCIN

2

Vaccine doses distributed [#]

Vaccine doses distributed

null

ACTIVE

2.70

2.7

96995-6

Vaccine doses distributed/100,000 population

NRto

Pt

^Event

Qn

null

VACCIN

2

Total vaccine doses distributed per 100,000 population

Vac doses dist per 100,000

null

ACTIVE

2.70

2.7

96996-4

People who have received first dose of vaccine

Num

Pt

^Population

Qn

null

VACCIN

2

People who have received first dose of vaccine [#] Population

People rcvd first dose of vaccine Pop

null

ACTIVE

2.70

2.7

96997-2

People who have received first dose of vaccine/100,000 population

NFr

Pt

^Population

Qn

null

VACCIN

2

Count of people who initiated vaccination per 100,000 population

Rcvd first dose of vaccine/100,00 pop

null

ACTIVE

2.70

2.7

96998-0

People who are fully vaccinated

Num

Pt

^Population

Qn

null

VACCIN

2

Count of people who are fully vaccinated in Population

People who fully vaccinated Pop

null

ACTIVE

2.70

2.7

96999-8

People who are fully vaccinated/100,000 population

NFr

Pt

^Population

Qn

null

VACCIN

2

Count of people who are fully vaccinated per 100,000 population

People who fully vaccinated/100,000 pop

null

ACTIVE

2.70

2.7

97000-4

Vaccine doses distributed for use in long term care facilities

Num

Pt

^Event

Qn

null

VACCIN

2

Vaccine doses distributed for use in long term care facilities [#]

Vaccine doses distributed to LTCFs

null

ACTIVE

2.70

2.7

97001-2

Vaccine administration tier

Type

Pt

^Event

Nom

null

VACCIN

2

Vaccine administration tier

null

ACTIVE

2.70

2.7

97002-0

People in long-term care facilities who have received first dose of vaccine

Num

Pt

^Population

Qn

null

VACCIN

2

Number of people in long-term care facilities who have received first dose of vaccine

# People in LTCFs rcvd 1st dose vaccine

null

ACTIVE

2.70

2.7

97003-8

People in long-term care facilities who are fully vaccinated

Num

Pt

^Population

Qn

null

VACCIN

2

Number of people in long-term care facilities who are fully vaccinated

# People in LTCFs fully vaccinated

null

ACTIVE

2.70

2.7

97004-6

Insulin type

Prid

Pt

Ser/Plas

Nom

LC/MS/MS

CHEM

1

Insulin type [Identifier] in Serum or Plasma by LC/MS/MS

Insulin Type SerPl LC/MS/MS

null

ACTIVE

2.70

2.7

97005-3

Maximum clot strength amplitude.kaolin+tissue factor induced

Len

Pt

Bld

Qn

Thromboelastography.resonance

COAG

1

Maximum amplitude kaolin+tissue factor induced [Length] in Blood by Resonance TEG

MA kaolin+TF Bld Res TEG

null

ACTIVE

2.70

2.7

9700-6

Procaine

MCnc

Pt

Ser/Plas

Qn

null

DRUG/TOX

1

Procaine [Mass/volume] in Serum or Plasma

Procaine SerPl-mCnc

null

ACTIVE

1.0i

2.73

97006-1

Maximum clot strength amplitude.kaolin+tissue factor induced

Len

Pt

Bld

Qn

null

COAG

1

Maximum amplitude kaolin+tissue factor induced [Length] in Blood

MA kaolin+TF Bld

null

ACTIVE

2.70

2.7

97007-9

Clot initiation.kaolin induced^post heparin neutralization

Time

Pt

Bld

Qn

Thromboelastography.resonance

COAG

1

Clot initiation.kaolin induced [Time] in Blood by Resonance TEG --post heparin neutralization

Clot init kao ind p hep neut Bld Res TEG

null

ACTIVE

2.70

2.7

97008-7

Clot initiation.kaolin+tissue factor induced

Time

Pt

Bld

Qn

null

COAG

1

Clot initiation.kaolin+tissue factor induced [Time] in Blood

Clot init kaolin+TF ind Bld

null

ACTIVE

2.70

2.7

97009-5

Activated clotting time.kaolin+tissue factor induced

Time

Pt

Bld

Qn

Calculated

COAG

1

Activated clotting time.kaolin+tissue factor induced of Blood by calculation

ACT Kaolin+TF Ind Bld Calc

null

ACTIVE

2.70

2.7

97010-3

Clot formation.kaolin+tissue factor induced

Time

Pt

Bld

Qn

null

COAG

1

Clot formation kaolin+tissue factor induced [Time] in Blood

CFT kaolin+TF ind Bld

null

ACTIVE

2.70

2.7

97011-1

Clot angle.kaolin+tissue factor induced

Angle

Pt

Bld

Qn

null

COAG

1

Clot angle kaolin+tissue factor induced in Blood

Clot angle kaolin+TF ind Bld

null

ACTIVE

2.70

2.7

97012-9

Reduction in clot strength.kaolin+tissue factor induced^30M post maximum clot amplitude

LenFr

Pt

Bld

Qn

null

COAG

1

Reduction in kaolin+tissue factor induced clot strength [Length fraction] in Blood --30 minutes post maximum clot amplitude

Lysis kao+TF ind clot 30M p MA LenFr Bld

null

ACTIVE

2.70

2.7

97013-7

Reduction in clot strength.kaolin induced^30M post maximum clot amplitude

LenFr

Pt

Bld

Qn

Thromboelastography.resonance

COAG

1

Reduction in kaolin induced clot strength [Length fraction] in Blood by Resonance TEG --30 minutes post maximum clot amplitude

Lys kao ind clt 30M p MA LenFr Bl ResTEG

null

ACTIVE

2.70

2.7

9701-4

sulfiSOXAZOLE

MCnc

Pt

Ser/Plas

Qn

null

DRUG/TOX

1

sulfiSOXAZOLE [Mass/volume] in Serum or Plasma

Sulfisoxaz SerPl-mCnc

null

ACTIVE

1.0i

2.7

97014-5

Maximum clot strength amplitude.tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited

Len

Pt

Bld

Qn

Thromboelastography.resonance

COAG

1

Maximum amplitude tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited [Length] in Blood by Resonance TEG

MA TF ind+IIb-IIIa inh Bld Res TEG

null

ACTIVE

2.70

2.7

97015-2

Maximum clot strength amplitude.tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited

Len

Pt

Bld

Qn

null

COAG

1

Maximum amplitude tissue factor induced+platelet glycoprotein IIb-IIIa receptor inhibited [Length] in Blood

MA TF ind+IIb-IIIa inh Bld

null

ACTIVE

2.70

2.7

97016-0

Fibrinogen

MCnc

Pt

Bld

Qn

Calculated

COAG

1

Fibrinogen [Mass/volume] in Blood by calculation

Fibrinogen Bld Calc-mCnc

null

ACTIVE

2.70

2.7

97017-8

Maximum clot strength amplitude.kaolin induced^after addition of heparinase

Len

Pt

Bld

Qn

null

COAG

1

Maximum amplitude kaolin induced [Length] in Blood --after addition of heparinase

MA kaolin P Hpase Bld

null

ACTIVE

2.70

2.7

97018-6

Maximum clot strength amplitude.activator F induced

Len

Pt

Bld

Qn

null

COAG

1

Maximum amplitude activator F induced [Length] in Blood

MA ActF Bld

null

ACTIVE

2.70

2.7

97019-4

Maximum clot strength amplitude.adenosine diphosphate induced

Len

Pt

Bld

Qn

null

COAG

1

Maximum amplitude ADP induced [Length] in Blood

MA ADP Bld

null

ACTIVE

2.70

2.7

97020-2

Maximum clot strength amplitude.arachidonate induced

Len

Pt

Bld

Qn

null

COAG

1

Maximum amplitude arachidonate induced [Length] in Blood

MA AA Bld

null

ACTIVE

2.70

2.7

97021-0

Reduction in clot strength.kaolin induced^30M post maximum clot amplitude

LenFr

Pt

Bld

Qn

null

COAG

1

Reduction in kaolin induced clot strength [Length fraction] in Blood --30 minutes post maximum clot amplitude

Lys of kao ind clot 30M p MA LenFr Bld

null

ACTIVE

2.70

2.7

9702-2

Terbutaline

MCnc

Pt

Ser/Plas

Qn

null

DRUG/TOX

1

Terbutaline [Mass/volume] in Serum or Plasma

Terbutaline SerPl-mCnc

null

ACTIVE

1.0i

2.7

97022-8

Clot strength.arachidonate inhibited

LenFr

Pt

Bld

Qn

Calculated

COAG

1

Clot strength arachidonate inhibited [Length fraction] in Blood by calculation

Clot strength AA inhib LenFr Bld Calc

null

ACTIVE

2.70

2.7

97023-6

Accountable health communities health-related social needs supplemental questions

-

Pt

^Patient

-

null

PANEL.SURVEY.GNHLTH

4

Accountable health communities (AHC) health-related social needs (HRSN) supplemental questions

null

ACTIVE

2.70

2.7

97024-4

aPTT mixing study panel

-

Pt

PPP

-

null

PANEL.COAG

1

aPTT mixing study panel - Platelet poor plasma

aPTT Mix Pnl PPP

null

ACTIVE

2.70

2.7

97025-1

BRAF gene.p.Val600 mutations

Prid

Pt

Tiss

Nom

Molgen

MOLPATH.MUT

1

BRAF gene V600 mutations [Identifier] in Tissue by Molecular genetics method Nominal

BRAF p.V600 mutations Tiss

null

ACTIVE

2.70

2.7

97026-9

Phosphatidylserine-prothrombin complex Ab.IgG & IgM panel

-

Pt

Ser/Plas

-

null

PANEL.COAG

1

Phosphatidylserine-prothrombin complex IgG and IgM panel - Serum or Plasma

PS-prothrom cmplx IgG IgM Pnl SerPl

null

ACTIVE

2.70

2.7

97027-7

Speaks a language other than English at home

Find

Pt

^Patient

Ord

null

SURVEY.GNHLTH

4

Speaks a language other than English at home

null

ACTIVE

2.70

2.7

97029-3

Spine Tango surgery follow-up 2017

-

Pt

^Patient

-

Spine Tango

PANEL.SURG

2

Spine Tango surgery follow-up 2017 Spine Tango

Spine Tango surgery f/u 2017 Spine Tango

ACTIVE

2.70

2.7

9703-0

Trihexyphenidyl

MCnc

Pt

Ser/Plas

Qn

null

DRUG/TOX

1

Trihexyphenidyl [Mass/volume] in Serum or Plasma

Trihexyphenidyl SerPl-mCnc

null

ACTIVE

1.0i

2.7

97030-1

Level of spine intervention

Find

Pt

^Patient

Nom

null

SURG

2

Level of spine intervention

null

ACTIVE

2.70

2.7

97031-9

Follow-up panel

-

Pt

^Patient

-

Spine Tango

PANEL.SURG

2

Follow-up panel Spine Tango

Spine Tango

ACTIVE

2.70

2.7

97032-7

Postoperative follow-up interval

Find

Pt

^Patient

Nom

null

H&P.HX

2

Postoperative follow-up interval

Postop follow-up interval

null

ACTIVE

2.70

2.7

97033-5

Postoperative work status

Find

Pt

^Patient

Nom

null

SURVEY.GNHLTH

4

Postoperative work status

null

ACTIVE

2.70

2.7

97034-3

Postoperative therapeutic goals or measures that were achieved

Find

Pt

^Patient

Nom

null

SURG

2

Postoperative therapeutic goals or measures that were achieved

Postop ther goals achieved

null

ACTIVE

2.70

2.7

97035-0

Postoperative therapeutic goals or measures that were partially achieved

Find

Pt

^Patient

Nom

null

SURG

2

Postoperative therapeutic goals or measures that were partially achieved

Postop ther goals partially achieved

null

ACTIVE

2.70

2.7

97036-8

Postoperative therapeutic goals or measures that were not achieved

Find

Pt

^Patient

Nom

null

SURG

2

Postoperative therapeutic goals or measures that were not achieved

Postop ther goals not achieved

null

ACTIVE

2.70

2.7

97037-6

Medication for spinal surgery or pathology

Find

Pt

^Patient

Nom

null

SURG

2

Medication for spinal surgery or pathology

Meds spinal surgery/pathology

null

ACTIVE

2.70

2.7

97038-4

Postoperative rehabilitation

Find

Pt

^Patient

Nom

null

SURG

2

Postoperative rehabilitation

Postop rehab

null

ACTIVE

2.70

2.7

97039-2

Overall outcome of spine surgery

Find

Pt

^Patient

Nom

null

SURG

2

Overall outcome of spine surgery

null

ACTIVE

2.70

2.7

970-4

Weak D Ag

PrThr

Pt

RBC^BPU

Ord

null

BLDBK

1

Weak D Ag [Presence] on Red Blood Cells from Blood product unit

Weak D Ag RBC BPU Ql

null

ACTIVE

1.0

2.7

97040-0

Postoperative follow-up care decision

Find

Pt

^Patient

Nom

null

SURG

2

Postoperative follow-up care decision

Postop follow-up care decision

null

ACTIVE

2.70

2.7

97041-8

Comments regarding postoperative follow-up

Find

Pt

^Patient

Nom

null

SURG

2

Comments regarding postoperative follow-up

Comments re: postop follow-up

null

ACTIVE

2.70

2.7

97042-6

Complications panel

-

Pt

^Patient

-

Spine Tango

PANEL.SURG

2

Complications panel Spine Tango

Complications pnl Spine Tango

ACTIVE

2.70

2.7

97043-4

Postoperative complication occurred

Find

Pt

^Patient

Ord

null

SURG

2

Postoperative complication occurred

Postop comp occurred

null

ACTIVE

2.70

2.7

97044-2

Postoperative complication timing

Find

Pt

^Patient

Nom

null

SURG

2

Postoperative complication timing

Postop complication timing

null

ACTIVE

2.70

2.7

97045-9

Postoperative complication type

Find

Pt

^Patient

Nom

null

SURG

2

Postoperative complication type

Postop complication type

null

ACTIVE

2.70

2.7

97046-7

Postoperative complication treatment needed

Find

Pt

^Patient

Nom

null

SURG

2

Postoperative complication treatment needed

Postop complication treatment

null

ACTIVE

2.70

2.7

97047-5

Postoperative complication effect on recovery

Find

Pt

^Patient

Nom

null

SURG

2

Postoperative complication effect on recovery

Postop comp effect on recvry

null

ACTIVE

2.70

2.7

9704-8

Spermatozoa

Morph

Pt

Semen

Nom

null

FERT

1

Spermatozoa [Morphology] in Semen

Sperm Smn

null

ACTIVE

1.0i

2.73

97048-3

Comments regarding postoperative complications

Find

Pt

^Patient

Nom

null

SURG

2

Comments regarding postoperative complications

Comments re: postop complications

null

ACTIVE

2.70

2.7

97049-1

p53 Ab

MCnc

Pt

Ser/Plas

Qn

IA

SERO

1

p53 Ab [Mass/volume] in Serum or Plasma by Immunoassay

p53 Ab SerPl IA-mCnc

null

ACTIVE

2.70

2.7

97050-9

Acinetobacter calcoaceticus-baumannii complex DNA

PrThr

Pt

Bld.pos growth

Ord

Non-probe.amp.tar

MICRO

1

Acinetobacter calcoaceticus-baumannii complex DNA [Presence] by NAA with non-probe detection in Positive blood culture

ACB complex DNA Bld Pos Ql NAA+non-probe

null

ACTIVE

2.70

2.7

97051-7

Interferon.beta

MCnc

Pt

Ser/Plas

Qn

null

CHEM

1

Interferon beta [Mass/volume] in Serum or Plasma

IFN-B SerPl-mCnc

null

ACTIVE

2.70

2.7

97052-5

Chemokine (C-C motif) ligand 2

MCnc

Pt

Ser/Plas

Qn

null

CHEM

1

Chemokine (C-C motif) ligand 2 [Mass/volume] in Serum or Plasma

CCL2 SerPl-mCnc

null

ACTIVE

2.70

2.7

97053-3

Macrophage inflammatory protein 1.alpha

MCnc

Pt

Ser/Plas

Qn

null

CHEM

1

Macrophage inflammatory protein 1 alpha [Mass/volume] in Serum or Plasma

MIP-1 alpha SerPl-mCnc

null

ACTIVE

2.70

2.71

97054-1

Granulocyte macrophage colony stimulating factor

MCnc

Pt

Ser/Plas

Qn

null

CHEM

1

Granulocyte macrophage colony stimulating factor [Mass/volume] in Serum or Plasma

GM-CSF SerPl-mCnc

null

ACTIVE

2.70

2.71

9705-5

Coccidioides immitis Ab.IgA

ACnc

Pt

Ser

Qn

null

MICRO

1

Coccidioides immitis IgA Ab [Units/volume] in Serum

C immitis IgA Ser-aCnc

null

ACTIVE

1.0i

2.73

97055-8

Finnish diabetes risk score panel

-

Pt

^Patient

-

FINDRISC

PANEL.CLIN.RISK

2

Finnish diabetes risk score panel FINDRISC

FINDRISC pnl FINDRISC

null

ACTIVE

2.70

2.7

97057-4

BMI score for risk calculation

Score

Pt

^Patient

Ord

null

H&P.HX

2

BMI score for risk calculation

BMI score for risk calc

null

ACTIVE

2.70

2.7

97058-2

Waist circumference score for risk calculation

Score

Pt

^Patient

Ord

null

H&P.PX

2

Waist circumference score for risk calculation

Waist circ score for risk calc

null

ACTIVE

2.70

2.7

97059-0

Physical activity at least 30M per D

Find

Pt

^Patient

Ord

null

H&P.HX

2

Physical activity at least 30 minutes per day

Physical activity min 30 M/day

null

ACTIVE

2.70

2.7

97060-8

Vegetable &or fruit frequency

NRat

Pt

^Patient

Ord

null

H&P.HX

2

Vegetable AndOr fruit frequency

null

ACTIVE

2.70

2.7

97062-4

High blood glucose

Hx

Pt

^Patient

Ord

null

H&P.HX

2

History of High blood glucose

Hx of High blood glucose

null

ACTIVE

2.70

2.7

9706-3

Coxiella burnetii phase 1 Ab.IgA

Titr

Pt

Ser

Qn

null

MICRO

1

Coxiella burnetii phase 1 IgA Ab [Titer] in Serum

C burnet Ph1 IgA Titr Ser

null

ACTIVE

1.0i

2.73

97063-2

Diabetes

Hx

Pt

^Family member

Ord

null

H&P.HX

2

Family history of Diabetes

Family hx of Diabetes

null

ACTIVE

2.70

2.7

97064-0

Total risk score

Score

Pt

^Patient

Qn

FINDRISC

CLIN.RISK

2

Total risk score FINDRISC

null

ACTIVE

2.70

2.7

97065-7

Medical history for preventive vaccination against COVID-19 (Coronavirus Disease 2019) - with mRNA vaccine

-

Pt

^Patient

-

null

PANEL.VACCIN

2

Medical history for preventive vaccination against COVID-19 (Coronavirus Disease 2019) - with mRNA vaccine

Hx for COVID -19 vaccine

null

ACTIVE

2.70

2.7

97066-5

Acute illness with fever

Find

Pt

^Patient

Ord

null

H&P.HX

2

Acute illness with fever

Acute ill w/fever

null

ACTIVE

2.70

2.7

97067-3

Allergic reaction to first COVID-19 vaccine dose

Find

Pt

^Patient

Ord

null

VACCIN

2

Allergic reaction to first COVID-19 vaccine dose

Aller react 1st COVID-19 dose

null

ACTIVE

2.70

2.7

97068-1

Chronic diseases &or immunodeficiency

Hx

Pt

^Patient

Ord

null

H&P.HX

2

History of Chronic diseases AndOr immunodeficiency

Hx chronic diseases/immunodeficiency

null

ACTIVE

2.70

2.7

97069-9

Coagulation disorder &or blood-thinning medication use

Hx

Pt

^Patient

Ord

null

H&P.HX

2

History of Coagulation disorder AndOr blood-thinning medication use

Hx coag disorder &/or bld-thin med

null

ACTIVE

2.70

2.7

97070-7

Adverse event following prior vaccination

Find

Pt

^Patient

Ord

null

VACCIN

2

Adverse event following prior vaccination

AE p vaccine

null

ACTIVE

2.70

2.7

9707-1

Coxiella burnetii phase 2 Ab.IgA

Titr

Pt

Ser

Qn

null

MICRO

1

Coxiella burnetii phase 2 IgA Ab [Titer] in Serum

C burnet Ph2 IgA Titr Ser

null

ACTIVE

1.0i

2.73

97071-5

Pregnant or nursing

Find

Pt

^Patient

Ord

null

H&P.HX

2

Pregnant or nursing

Pregnant/Nursing

null

ACTIVE

2.70

2.7

97072-3

Vaccinated in last 14 D

Find

14D

^Patient

Ord

null

VACCIN

2

Vaccinated in last 14 days

Vacc last 14 D

null

ACTIVE

2.70

2.7

97073-1

Received COVID-19 vaccine

Find

Pt

^Patient

Ord

null

VACCIN

2

Received COVID-19 vaccine

Rcvd COVID-19 vaccine

null

ACTIVE

2.70

2.7

97074-9

Mean score

Score

Pt

^Patient

Qn

CRBS

SURVEY.COVID

4

Mean score [CRBS]

null

ACTIVE

2.70

2.71

97075-6

Total score

Score

Pt

^Patient

Qn

CAS

SURVEY.COVID

4

Total score [CAS]

null

ACTIVE

2.70

2.71

97076-4

Common news sources

Type

Pt

^Patient

Nom

null

SURVEY.COVID

4

Common news sources

null

ACTIVE

2.70

2.71

97077-2

Time spent per day getting information about COVID-19 &or its impact

Find

Pt

^Patient

Ord

null

SURVEY.COVID

4

Time spent per day getting information about COVID-19 and/or its impact

null

ACTIVE

2.70

2.71

97078-0

Effect of friends, family or neighbors as source of information on mental health

Find

Pt

^Patient

Ord

null

SURVEY.COVID

4

Effect of friends, family or neighbors as source of information on mental health

null

ACTIVE

2.70

2.71

97079-8

Effect of local government officials as source of information on mental health

Find

Pt

^Patient

Ord

null

SURVEY.COVID

4

Effect of local government officials as source of information on mental health

null

ACTIVE

2.70

2.71

97080-6

Effect of national government officials as source of information on mental health

Find

Pt

^Patient

Ord

null

SURVEY.COVID

4

Effect of national government officials as source of information on mental health

null

ACTIVE

2.70

2.71

97081-4

Effect of national and international health officials as source of information on mental health

Find

Pt

^Patient

Ord

null

SURVEY.COVID

4

Effect of national and international health officials as source of information on mental health

null

ACTIVE

2.70

2.71

97082-2

Effect of print or online news as source of information on mental health

Find

Pt

^Patient

Ord

null

SURVEY.COVID

4

Effect of print or online news as source of information on mental health

null

ACTIVE

2.70

2.71

97083-0

Effect of radio or podcast as source of information on mental health

Find

Pt

^Patient

Ord

null

SURVEY.COVID

4

Effect of radio or podcast as source of information on mental health

null

ACTIVE

2.70

2.71